Malignancies in Transplanted Patients

Uppsala University95 enrolled

Overview

The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neoplasms

Interventions

Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detectionOTHER

Switch from calcineurin inhibitor to an mTOR inhibitorDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients willing and capable of giving written informed consent of participation in the project * Patients with a previous diagnosed or presently diagnosed or reoccurrence of a malignancy (other then basal cell carcinoma) Exclusion Criteria: * Patients with a primary liver cancer as cause of the transplantation

Locations (1)

Department of Surgery, Section of Transplantation Surgery, Uppsala University Hospital

Uppsala, Sweden

Outcomes

Primary Outcomes

Patient survival

After inclusion

Time frame: 12 months, 2 years, 3 years

Secondary Outcomes

Graft survival

After inclusion

Time frame: 12 months, 2 years, 3 years

ImmuKnow Assay value

Time frame: 12 months

Tumour progression/regression/reoccurrence

Time frame: 12 months, 2 years, 3 years

Maintained switch of immunosuppression from calcineurin inhibitor to mTOR inhibitor

Time frame: 3 years

Kidney function

Creatinine measure

Time frame: 12 months, 2 years, 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.